Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.90
-0.1500-1.86%
Pre-market: 8.120.2200+2.78%05:08 EDT
Volume:1.76M
Turnover:13.99M
Market Cap:715.45M
PE:-3.27
High:8.18
Open:8.00
Low:7.74
Close:8.05
52wk High:10.82
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:1.05
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:14.31
PE(LYR):-2.61

Loading ...

Top Verastem Executives Quietly Cash Out in Fresh Stock Moves

TIPRANKS
·
Jun 25

Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says

MT Newswires Live
·
Jun 24

Verastem (VSTM) Gets a Buy from Alliance Global Partners

TIPRANKS
·
Jun 24

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)

TIPRANKS
·
Jun 24

Verastem Price Target Maintained with a $18.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Verastem (VSTM) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jun 24

BRIEF-Versus-7375 Demonstrates Clinical Activity With A Favorable Safety And Tolerability Profile In Target-D 101

Reuters
·
Jun 24

Verastem Advances VS-7375 with Promising Early Trial Data

TIPRANKS
·
Jun 24

Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors

MT Newswires Live
·
Jun 24

Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375

Dow Jones
·
Jun 24

Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial

TIPRANKS
·
Jun 24

Verastem says KRAS G12D inhibitor VS-7375 shows early activity in Phase 1/2 TARGET-D 101 trial across solid tumors

Reuters
·
Jun 24

Verastem - VS-7375 Shows Anti-Tumor Activity With Anti-Egfr Therapy or Standard Chemotherapy

THOMSON REUTERS
·
Jun 24

Verastem - Co and Erasca Announce Intent to Evaluate VS-7375 With Eras-15 in Kras G12d Tumors

THOMSON REUTERS
·
Jun 24

VS-7375 Demonstrates Clinical Activity With a Favorable Safety and Tolerability Profile in Target-D 101 Phase 1/2 Clinical Trial in Patients With Advanced Kras G12d-Mutated Solid Tumors

THOMSON REUTERS
·
Jun 24

Verastem - VS-7375 Safety Profile Mainly Low-Grade Gi Events That Decrease After Cycle 1

THOMSON REUTERS
·
Jun 24

Verastem price target lowered to $8 from $15 at Jefferies

TIPRANKS
·
Jun 24

Verastem Is Maintained at Buy by Jefferies

Dow Jones
·
Jun 23

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron

Reuters
·
Jun 17

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM) and ClearPoint Neuro (CLPT)

TIPRANKS
·
Jun 17